Drug intelligence / Profile preview

EyeStrong

Development stage: Preclinical
Lead developer: Lamark
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

EyeStrong is a preclinical-stage thermostable monoclonal antibody being developed by Lamark Biotech for the treatment of wet age-related macular degeneration (wet AMD). The biologic is engineered using Lamark's proprietary Proteostrong™ technology, which is designed to enhance the stability and enable a sustained-release formulation of the antibody. EyeStrong acts by inhibiting a novel neoangiogenesis pathway, although the specific molecular target remains undisclosed by the sponsor. The development of EyeStrong aims to provide a long-acting therapeutic option that reduces the frequency of administration for patients with neovascular retinal diseases.

Brand names: EyeStrong
Other names: EyeStrong

Beyond the preview

Go deeper on EyeStrong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeStrong.

Explore the full profile